Teva Pharmaceutical Industries Limited (NYSE:TEVA)‘s stock had its “buy” rating reissued by Gabelli in a research report issued on Wednesday.

A number of other equities analysts have also recently weighed in on the company. TheStreet cut Teva Pharmaceutical Industries Limited from a “c-” rating to a “d+” rating in a research note on Friday, August 25th. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 price target on the stock in a research note on Monday, July 24th. Credit Suisse Group cut Teva Pharmaceutical Industries Limited from a “neutral” rating to an “underperform” rating and dropped their price target for the stock from $25.00 to $13.00 in a research note on Wednesday, August 23rd. Royal Bank Of Canada reissued an “outperform” rating and issued a $37.00 price target (down previously from $38.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, July 17th. Finally, Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and issued a $21.00 price target (down previously from $28.00) on shares of Teva Pharmaceutical Industries Limited in a research note on Thursday, August 31st. Five investment analysts have rated the stock with a sell rating, nineteen have issued a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of $32.65.

Teva Pharmaceutical Industries Limited (NYSE TEVA) traded down 0.3963% during midday trading on Wednesday, hitting $19.2534. 11,444,317 shares of the company traded hands. The stock has a 50 day moving average of $20.60 and a 200 day moving average of $28.94. Teva Pharmaceutical Industries Limited has a 12-month low of $15.22 and a 12-month high of $52.66. The stock’s market cap is $19.56 billion.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.06 by ($0.07). The company had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.72 billion. Teva Pharmaceutical Industries Limited had a positive return on equity of 15.96% and a negative net margin of 25.18%. The company’s revenue for the quarter was up 12.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.25 EPS. Equities research analysts predict that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Teva Pharmaceutical Industries Limited’s (TEVA) Buy Rating Reiterated at Gabelli” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/13/teva-pharmaceutical-industries-limiteds-teva-buy-rating-reiterated-at-gabelli.html.

Hedge funds and other institutional investors have recently modified their holdings of the business. San Francisco Sentry Investment Group CA bought a new position in Teva Pharmaceutical Industries Limited in the 2nd quarter worth approximately $106,000. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 7.8% in the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock worth $116,000 after buying an additional 261 shares during the period. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 74.7% in the 2nd quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock worth $122,000 after buying an additional 1,571 shares during the period. FNY Managed Accounts LLC bought a new position in Teva Pharmaceutical Industries Limited in the 1st quarter worth approximately $123,000. Finally, Sterling Investment Advisors Ltd. increased its position in Teva Pharmaceutical Industries Limited by 2.6% in the 1st quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock worth $125,000 after buying an additional 100 shares during the period. 56.87% of the stock is currently owned by institutional investors.

Teva Pharmaceutical Industries Limited Company Profile

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.